239 related articles for article (PubMed ID: 19824039)
1. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.
Xiong G; Husseiny MI; Song L; Erdreich-Epstein A; Shackleford GM; Seeger RC; Jäckel D; Hensel M; Metelitsa LS
Int J Cancer; 2010 Jun; 126(11):2622-34. PubMed ID: 19824039
[TBL] [Abstract][Full Text] [Related]
2. Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.
Xu X; Hegazy WA; Guo L; Gao X; Courtney AN; Kurbanov S; Liu D; Tian G; Manuel ER; Diamond DJ; Hensel M; Metelitsa LS
Cancer Res; 2014 Nov; 74(21):6260-70. PubMed ID: 25213323
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of the Salmonella pathogenicity island 2-mediated inhibition of antigen presentation in dendritic cells.
Halici S; Zenk SF; Jantsch J; Hensel M
Infect Immun; 2008 Nov; 76(11):4924-33. PubMed ID: 18765734
[TBL] [Abstract][Full Text] [Related]
5. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
[TBL] [Abstract][Full Text] [Related]
6. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
Sharma RK; Schabowsky RH; Srivastava AK; Elpek KG; Madireddi S; Zhao H; Zhong Z; Miller RW; Macleod KJ; Yolcu ES; Shirwan H
Cancer Res; 2010 May; 70(10):3945-54. PubMed ID: 20406989
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.
Ciesielski MJ; Apfel L; Barone TA; Castro CA; Weiss TC; Fenstermaker RA
Cancer Immunol Immunother; 2006 Dec; 55(12):1491-503. PubMed ID: 16485128
[TBL] [Abstract][Full Text] [Related]
8. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
Ciesielski MJ; Ahluwalia MS; Munich SA; Orton M; Barone T; Chanan-Khan A; Fenstermaker RA
Cancer Immunol Immunother; 2010 Aug; 59(8):1211-21. PubMed ID: 20422411
[TBL] [Abstract][Full Text] [Related]
9. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Salmonella enterica type III secretion system effector proteins as carriers for heterologous vaccine antigens.
Hegazy WA; Xu X; Metelitsa L; Hensel M
Infect Immun; 2012 Mar; 80(3):1193-202. PubMed ID: 22252866
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intracellular activated promoters for generation of Salmonella-based vaccines.
Xu X; Husseiny MI; Goldwich A; Hensel M
Infect Immun; 2010 Nov; 78(11):4828-38. PubMed ID: 20732994
[TBL] [Abstract][Full Text] [Related]
12. Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection.
Xu C; Zhang BZ; Lin Q; Deng J; Yu B; Arya S; Yuen KY; Huang JD
BMC Infect Dis; 2018 Apr; 18(1):195. PubMed ID: 29699491
[TBL] [Abstract][Full Text] [Related]
13. Functional transfer of Salmonella pathogenicity island 2 to Salmonella bongori and Escherichia coli.
Hansen-Wester I; Chakravortty D; Hensel M
Infect Immun; 2004 May; 72(5):2879-88. PubMed ID: 15102800
[TBL] [Abstract][Full Text] [Related]
14. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis.
Xiang R; Luo Y; Niethammer AG; Reisfeld RA
Immunol Rev; 2008 Apr; 222():117-28. PubMed ID: 18363997
[TBL] [Abstract][Full Text] [Related]
15. Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors.
Panthel K; Meinel KM; Sevil Domènech VE; Trülzsch K; Rüssmann H
Int J Med Microbiol; 2008 Jan; 298(1-2):99-103. PubMed ID: 17719275
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.
Charalambous A; Oks M; Nchinda G; Yamazaki S; Steinman RM
J Immunol; 2006 Dec; 177(12):8410-21. PubMed ID: 17142738
[TBL] [Abstract][Full Text] [Related]
17. Recombinant vaccines based on translocated effector proteins of Salmonella Pathogenicity Island 2.
Husseiny MI; Wartha F; Hensel M
Vaccine; 2007 Jan; 25(1):185-93. PubMed ID: 16887239
[TBL] [Abstract][Full Text] [Related]
18. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.
Srivastava AK; Sharma RK; Yolcu ES; Ulker V; MacLeod K; Dinc G; Shirwan H
PLoS One; 2012; 7(11):e48463. PubMed ID: 23144888
[TBL] [Abstract][Full Text] [Related]
19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
20. Virulent Salmonella enterica serovar typhimurium evades adaptive immunity by preventing dendritic cells from activating T cells.
Tobar JA; Carreño LJ; Bueno SM; González PA; Mora JE; Quezada SA; Kalergis AM
Infect Immun; 2006 Nov; 74(11):6438-48. PubMed ID: 17057096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
